Author Archives: Biovaxys

BioVaxys Announces Results from The Ohio State University Pan-Sarbecovirus Animal Study

VANCOUVER, BC, December 16th, 2022 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that possibly based on the selected study design, results from The Ohio State University (“Ohio State”) animal study, its collaborator on the development of BioVaxys’ pan-sarbecovirus vaccine, did not demonstrate that immunization of study animals with BVX-1021, followed […]

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

VANCOUVER, BC, December 1st, 2022 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company’s bi-haptenized autologous ovarian cancer vaccine. The complete manufacturing of BVX-0918 from a cancer patient’s ovarian tumor now validates the production protocols that had been in […]

BioVaxys Closes First Tranche of Non-Brokered Private Placement

Vancouver, British Columbia, November 28, 2022, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has closed the first tranche (“Tranche 1”) of a non-brokered private placement (the “Private Placement”).  Pursuant to Tranche 1 of the Private Placement, the Company has issued 940,000 units (“Units”) at a price […]

BioVaxys Announces Completed Private Placement And Debt Settlement

Vancouver, British Columbia, November 9, 2022, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has completed a non-brokered private placement (the “Private Placement”) consisting of 4,050,000 units (“Units”) at a price of $0.10 per Unit for total gross proceeds of $405,000. Each Unit consists of one common […]

BioVaxys Announces Debt Settlement

Vancouver, British Columbia, October 27, 2022 – BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has agreed to settle an aggregate of $150,000 in debt with one vendor through the issuance of common shares to be issued at a deemed price of $0.20 per common share (the […]

BioVaxys Announces Completed Debt Settlement

VANCOUVER, British Columbia, Oct. 14, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC-QB: BVAXF) (“BioVaxys” or the “Company”) announces that, further to its news release dated October 6, 2022, it has settled an aggregate of $300,000 in debt through the issuance of common shares issued at a deemed price of $0.15 per common […]

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare VANCOUVER, BC, October 6th, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that it has executed a binding Term Sheet (“Term Sheet” or “Agreement”) with Procare Health Iberia, S.L. (“Procare Health”), of Barcelona, Spain (“Procare Health”), for […]

BioVaxys Further Expands Vaccines Intellectual Property Portfolio

VANCOUVER, BC, September 28th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that in an action that further expands the value of their IP portfolio, the Company has broadened the patent coverage for its viral vaccine platform by filing an international patent application through the Patent Cooperation Treaty (“PCT”) […]

BioVaxys Announces New Chief Financial Officer

VANCOUVER, BC , August 8th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial Officer.  Mr. Loverock is replacing Mr. Lachlan McLeod, who has been the acting CFO following the transition from Lions Bay Mining Inc. to BioVaxys in […]

BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal study

VANCOUVER, BC, September 6th, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the Company’s vaccine for SARS-CoV, which is being used in the collaboration with The Ohio […]